Ovarian cancer, which affects the female reproductive system, has been such a monster over the last decades. And more often than not, it goes undetected until it has ambushed the pelvis and abdomen. However, according to VBL Therapeutics (NASDAQ: VBLT), there is some hope of managing it before it early enough and before it can cause much damage. The clinical-stage biopharmaceutical company says it has an update on the OVAL Phase 3 registration, enhancing the clinical trial of VB-111 in ovarian cancer. The update shall be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
VB-111, which is positioned to treat a wide range of solid tumors, is the lead candidate in VBL’s most advanced program, the anti-cancer gene therapy program. The OVAL study will enroll about 400 patients, and its purpose is to support excellence in the field of gynecologic malignancies. A Phase 1 trial that enrolled more than 300 cancer patients demonstrated activity signals in an “all comers.”
Previously, VB-111 has proven to be of survival benefit in Phase 2 clinical trials in radioiodine-refractory thyroid cancer.
According to the CEO of VBL Therapeutics, Dror Harats says that the continued progress of the OVAL clinical trial is very promising. And that they are hopeful that a pivotal study will provide a lasting solution. It is also worth mentioning that VB-111 has received orphan drug designation in the US and Europe plus a Fast Track designation by the FDA. The latter will come in handy in the prolongation of survival in patients with glioblastoma.
Other Programs by VBL Therapeutics
The Israel-based VBL Therapeutics was previously Vascular Biogenics Ltd and began operations in 2008. Over the years, the company has developed several programs and platform technologies, one of them being a particular protein called MOSPD2. It controls the directed cell movement of immune and tumor cells. And in another program, the company is developing bi-specific antibodies, the aim being to bring together tumor cells via MOSPD2 and T-cells via CD3.